PTH (1-34): A novel anabolic drug for the treatment of osteoporosis

Southern Medical Journal

Volumn 98, Issue 11, 2005, Pages 1114-1117

  Holick, Michael F ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Anabolic drugs; Osteoblast; Osteoporosis; Parathyroid hormone

Indexed keywords

ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PARATHYROID HORMONE[1-34]; RECOMBINANT PARATHYROID HORMONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D;

BONE BIOPSY; BONE DENSITY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; LEG CRAMP; LUMBAR SPINE; NONHUMAN; OSTEOPOROSIS; PARATHYROID GLAND; POSTMENOPAUSE; REVIEW; RISK ASSESSMENT; RISK REDUCTION;

ANABOLIC AGENTS; ANIMALS; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; TERIPARATIDE;

EID: 28844494405     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.SMJ.0000140864.78760.8D     Document Type: Review

References (15)

1. Breimer L, Sourander P. The discovery of the parathyroid glands in 1880: triumph and tragedy of Ivar Sandstrom. Bull Hist Med 1981;55:558-563.
2. Eknoyan G. A history of the parathyroid glands. Am J Kidney Dis 1995;26:801-807.
3. Bauer W, Aub AC, Albright F. Studies of calcium and phosphorus metabolism, V: a study of the bone trabeculae as a readily available reserve of calcium. J Exp Med 1929;49:145-161.
4. Selye H. On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol. Endocrinology 1932;16:547-558.
5. Dobnig H, Turner RT. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997;138:4607-4612.
6. Sato M, Westmore M, Clendenon J, et al. Three-dimensional modeling of the effects of parathyroid hormone on bone distribution in lumbar vertebrae of ovariectomized cynomolgus macaques. Osteoporos Int 2000;11:871-880.
7. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350:550-555.
8. Roe EB, Sanchez SD, del Puerto GA, et al. Parathyroid hormone 1-34 [hPTH(1-34)] and estrogen produce dramatic bone density increases in postmenopausal osteoporosis: results from a placebo-controlled randomized trial. J Bone Miner Res 1999;14(Suppl 1):S137.
9. Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest 1998;102:1627-1633.
10. Lane NE, Sanchez S, Modin GW, et al. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000;15:944-591.
11. Orwoll E, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17.
12. Neer RM, Arnaud CD, Zanchetta JR, et al. Recombinant human PTH [rhPTH(1-34)] reduces the risk of spine and non-spine fractures in postmenopausal osteoporosis. N Engl J Med 2001;344:1434-1441.
13. Mitlak BH, Williams DC, Bryant HU, et al. Intermittent administration of bovine PTH-(1-34) increases serum 1,25-dihydroxyvitamin D concentrations and spinal bone density in senile (23 month) rats. J Bone Min Res 1992;7:479-484.
14. Vegni FE, Corradini C, Privitera G, et al, the PaTH (Parathyroid Hormone and Alendronate) Study Investigators. Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis. N Engl J Med 2004;350:189-192.
15. Finkelstein JS, Hayes MSN, Hunzelman JL, et al. The effects of parathyroid hormone, aleudronate, or both in men with osteoporosis. N Engl J Med 2003;349:1216-1226.